ClinicalTrials.gg
CompletedNCT00127140Updated Sep 28, 2015

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

A Phase 1 interventional study of vorinostat in Lymphoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing vorinostat in Lymphoma — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Lymphoma.

Enrollment
13th of 19
10 · median 17
Started
2005
with 1 other
Phase 1
7 of 20
none open now
Registered
3rd of 20
by date
Lead sponsor
4 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Lymphoma, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2005, is one of 7 in phase 1, and was the 3rd registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

None of the 20 studies testing vorinostat in Lymphoma is open now. The open studies under Lymphoma, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Lymphoma as a file.
02

Study summary

The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral vorinostat in patients with malignant lymphoma.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who after complete or partial response, or ineffective in previous chemotherapy

Exclusion criteria

Exclusion Criteria:

  • Patients with history of chemotherapy, antibody therapy, radiotherapy, during the previous 4 weeks (6 months for radioisotope-labeled antibody)
  • Any uncontrolled concomitant illness
  • Are pregnant or breast-feeding
  • Serious drug or food allergy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Vorinostat

    Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.

    Drug: vorinostat

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants Experiencing Dose-Limiting Toxicities (DLTs)

    Time frame: Up to 21 days

Secondary outcomes

  1. Area Under the Curve (AUC) of Vorinostat After Single Oral Dosing

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose on Days 1 and 17

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Watanabe T, Kato H, Kobayashi Y, Yamasaki S, Morita-Hoshi Y, Yokoyama H, Morishima Y, Ricker JL, Otsuki T, Miyagi-Maesima A, Matsuno Y, Tobinai K. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci. 2010 Jan;101(1):196-200. doi: 10.1111/j.1349-7006.2009.01360.x. Epub 2009 Sep 10. PubMed 19817748 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2005
First posted
Aug 5, 2005
Start
Jun 2005
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Last update
Sep 28, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00127140
Responsible party
Sponsor
First posted
Aug 5, 2005
Start date
Jun 2005
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Sep 28, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion